Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640773 | 0.81 | PDCD1 (0.42) | MALT1 | |
| SCHEMBL6641341 | 0.80 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2MALT1 | |
| SCHEMBL6640639 | 0.78 | HRH3 (0.52) | SLC6A4HTR2AHTR2CHTR3A | |
| SCHEMBL6639763 | 0.77 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2MALT1 | |
| SCHEMBL7600071 | 0.74 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL18616440 | 0.70 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| Litoxetine SCHEMBL119884 | 0.66 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| Litoxetine SCHEMBL30505553 | 0.66 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL6636900 | 0.66 | HTR2C (0.46) | HTR2AHTR2C | |
| Litoxetine SCHEMBL241925 | 0.65 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1078928-B1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2004-05-12 | — | — | EP | disclosed |
| US-6486171-B2 | USEFUL IN THE TREATMENT OF SOME CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING AS AN ANTIDEPRESSANT; 4-(1-(2-NAPHTHYL)ETHYL)-4- PIPERIDINYL)THIENO(3,2-C)PYRIDINE, FOR EXAMPLE | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20020161228-A1 | Piperidine compounds | ADIR ET COMPAGNIE | 2002-10-31 | — | — | US | disclosed |
| US-6399616-B1 | 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION | LES LABORATOIRES SERVIER (FR) | 2002-06-04 | — | — | US | disclosed |
| EP-1078928-A1 | Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161228-A1 | Piperidine compounds | OTC, NPPA, AQP4 | SLC6A2 1089/4885SLC6A4 1106/4885SLC6A3 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.